Healthcare

In its results announcement dated 31 August 2026, Adheris reported FY26 revenue of $34.0 million, down 46% from $63.0 million, reflecting lower customer renewals during the prior pharma budget period and lower bookings in the first half. Gross profit fell 56% to $14.6 million …

In its Appendix 4C release dated 23 October 2026, Arovella reported that it reached clinical readiness during the September 2026 quarter, with the first two batches of ALA-101 manufactured and released for patient use.

In its announcement dated 31 August 2026, Avecho said recruitment has recommenced for the final stage of its pivotal Phase III trial of a TPM-enhanced CBD soft-gel capsule for insomnia. Approximately 320 additional participants are to be enrolled in the second and final cohort, …

In its announcement dated 21 October 2026, Cleo stated that its prototype ovarian cancer screening test met or exceeded all pre-defined performance targets in its first proof-of-concept study. The retrospective study involved 247 women, comprising 87 healthy individuals, 67 women with benign gynaecological disease …

In its announcement dated 7 October 2026, Cyclopharm said the consensus was published in the October 2026 issue of the Chinese Journal of Tuberculosis and Respiratory Diseases, a peer-reviewed journal of the Chinese Medical Association. The first of its ten recommendations states that 99mTc-Technegas …

In its announcement dated 25 September 2026, Healius said it had signed a binding agreement for the sale of Agilex Biolabs Pty Ltd, a wholly owned subsidiary, to a subsidiary of Novotech Health Holdings Pte Ltd. The transaction values the business at an enterprise …

In its announcement dated 21 October 2026, Invion said it had secured two complementary financing arrangements expected to cover up to approximately 85% of its current and future clinical development programs, including the ongoing non-melanoma skin cancer (NMSC) trial and upcoming anogenital cancer trials. …